|Day Low/High||0.07 / 0.09|
|52 Wk Low/High||0.07 / 10.30|
Here are the highlights from the second full day of clinical data presentations at ASCO 2010.
Delcath's PHP system delays liver tumor progression by 6.5 months, according to updated results from a phase III study.
The American Society of Clinical Oncology -- ASCO -- annual meeting kicks off today. Here are the highlights.
Here's a list of June's potentially stock-moving biotech events.
With so much pattern confusion and a total dependency on the overnight markets for guidance, there isn't much to do right now.
Delcath Systems CEO Eamonn Hobbs talks to TheStreet about his company's recently released cancer treatment data.
Here's a primer for the American Society of Clinical Oncology's abstract release tomorrow night.
Our biotech watchdog answers readers' questions and tweets about drug- and health care-related stocks.
Cramer says analysts have been derelict in staying on top of what is happening at companies and updating their estimates during the quarter.
Delcath says phase III study exceeds expectations; company will seek FDA approval.
Here are ten biotech and drug companies facing upcoming, potentially stock-moving events.
In a bonus edition of Mailbag, our biotech columnist answers readers' questions about healthcare stocks and the FDA.
Delcath will soon release results from a phase III study of its drug-device system to clear tumors from the liver.
News of clinical trial results can make or break a drug. Here are ten companies expected to announce important results in coming months.
Guests include Christine Benz, author of 30-Minute Money Solutions, Kent Croft, portfolio manager for the Croft Value fund and Marshall Berol, portfolio manager for the Encompass Fund.
The Encompass Fund, which has doubled in value this year, is staking its fortunes on a spike in uranium prices, driven by demand for nuclear energy.
Delcath Systems liver cancer drug candidate receives special designation by FDA
Delcath Systems cancer drug candidate receives additional special designation by FDA
It's not clear how this tiny biotech's pain patch can compete with a host of rivals, large and small.
More discussion of Sangamo's SB-509, revisiting Delcath and questioning YM Bio's chances with nimo.
Xoma's apparent lack of interest in a buyout may not serve investors in the near term.
Pointing the finger at the FDA isn't a sound investment strategy.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.